

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
SUSAN BANBURY ET AL.)	Examiner: Shirley V. Gembeh
)	
Application No.: 10/534,117)	Art Unit: 1618
)	
Filed: October 6, 2005)	Confirmation No.: 2448
)	
For: FORMULATIONS)	
CONTAINING SUBSTITUTED)	
IMIDAZOLE DERIVATIVES)	April 28, 2011

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the attached PTO/SB/08a form. In accordance with current practice, no copies of any U.S. patent document are attached. A copy of the listed non-U.S. patent document is attached.

This Information Disclosure Statement is to make of record patent documents cited in an Official Letter issued in corresponding Polish Patent Application No. P-375 565, dated December 15, 2010. A copy of that letter is attached.

WO 93/13074, U.S. Patent No. 4,968,692, U.S. Patent No. 5,079,018 and U.S. Patent No. 5,120,549, cited in the Official Letter, were previously made of record in this application.

CONCLUSION

It is respectfully requested that the above information be considered by the Examiner, and that an initialed copy of the attached PTO/SB/08a form be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

/Elizabeth F. Holowacz/
Elizabeth F. Holowacz
Attorney for Applicants
Registration No.: 42,667

FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
Facsimile: (212) 218-2200